SHERIDAN, WYOMING – May 19, 2025 – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has announced the successful pricing of a €1 billion dual-tranche bond issuance under its European Medium Term Note (EMTN) program, marking a strategic step to reinforce its capital structure and advance sustainable investment goals.
SHERIDAN, WYOMING – May 17, 2025 – Danaher Corporation is reinforcing its position at the forefront of life sciences and diagnostics innovation through its Beacon program—an initiative designed to transform cutting-edge academic research into scalable, market-ready solutions. Spearheaded by Vanessa Almendro, PhD, MBA, Vice President, Head of Science and Technology Innovation at Danaher, the Beacon model exemplifies how strategic academic-industry collaboration can generate high-impact innovations aligned with real-world healthcare and biotechnology challenges.
SHERIDAN, WYOMING – May 9, 2025 – LivaNova PLC, a global leader in medical technology, announced strong first-quarter 2025 results today, demonstrating continued growth and operational efficiency. The company reported high single-digit revenue growth, including double-digit organic revenue increases, as well as expanding operating margins. LivaNova also raised its full-year 2025 revenue guidance, taking into account the impact of the SNIA environmental liability and current tariffs.
SHERIDAN, WYOMING – May 9, 2025 – LivaNova PLC, a leading global medical technology company, has announced 12-month top-line data from its OSPREY clinical trial. The study demonstrates promising results for the aura6000™ System, an investigational device designed to treat moderate to severe obstructive sleep apnea (OSA). The data highlights sustained improvements in key health metrics, positioning the aura6000™ as a potential breakthrough in OSA management.
SHERIDAN, WYOMING – May 09, 2025 – Globus Medical, Inc. (NYSE: GMED), a leading provider of musculoskeletal solutions, has announced its financial results for the first quarter of 2025. The company reported worldwide net sales of $598.1 million, reflecting a 1.4% decrease year-over-year, primarily driven by a slowdown in Enabling Technology deal closures and temporary supply chain disruptions. Despite these challenges, Globus Medical saw notable growth in its core U.S. spine business and remains optimistic about its future prospects.
SHERIDAN, WYOMING – May 9, 2025 – Globus Medical, Inc. (NYSE: GMED), a prominent player in the musculoskeletal solutions industry, has reported its financial results for the first quarter of 2025. Despite a slight dip in global net sales, the company remains confident in its ability to drive long-term growth and innovation. The results reflect challenges faced in certain areas, including slower deal closures in Enabling Technology, but also showcase the company’s strong positioning in the U.S. spine business.
SHERIDAN, WYOMING – May 9, 2025 – Enovis Corporation (NYSE: ENOV), a global leader in medical technology, has appointed Damien McDonald as its new Chief Executive Officer, effective May 12, 2025. McDonald, who will also join the Enovis Board of Directors following the Company’s 2025 Annual Meeting of Stockholders, succeeds Matt Trerotola, who has announced his retirement. This strategic leadership transition positions Enovis for continued growth and innovation in the medical technology sector.
SHERIDAN, WYOMING – May 8, 2025 – Invacare is proud to announce the launch of its global fundraiser, Move For Mobility 2025, which aims to provide life-changing wheelchairs to individuals in need around the world. The initiative brings together Invacare employees, ambassadors, clients, and partners in a worldwide effort to raise awareness and funds for the Free Wheelchair Mission, an organization committed to delivering wheelchairs at no cost to people with disabilities in remote communities.
SHERIDAN, WYOMING – May 8, 2025 – B. Braun Group has demonstrated resilience and strategic growth amidst challenging global conditions, reporting a 4.4% increase in sales for the 2024 fiscal year. The company’s focus on innovation, operational efficiency, and modern technology investments has contributed to a solid financial performance, reaffirming its commitment to advancing healthcare solutions worldwide.
SHERIDAN, WYOMING – May 8, 2025 – Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care, today revealed the successful outcome of all proposed resolutions at its 2025 Annual General Meeting (AGM). Among the significant decisions, shareholders approved key appointments to the Board, including the election of Deborah Di Sanzo, and granted approval for the 2024 Compensation Report and the Report on Non-Financial Matters.